Prostate Cancer
Targeting Tumour Plasticity in Advanced Prostate Cancer
Nearly 20% of advanced prostate cancer patients relapse on potent androgen receptor (AR) targeted therapies with a highly aggressive disease called treatment induced neuroendocrine prostate cancer (NE...
Read More